Carmignac Gestion Merus N.V. Transaction History

Carmignac Gestion

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$39.81 - $60.2 $123,649 - $186,981	3,106 Added 7.93%	42,278 $2.5 Million
Q1 2024 May 14, 2024	SELL	$28.03 - $51.82 $10.2 Million - $18.9 Million	-364,689 Reduced 90.3%	39,172 $1.76 Million
Q4 2023 Feb 13, 2024	SELL	$20.06 - $28.66 $1.01 Million - $1.45 Million	-50,470 Reduced 11.11%	403,861 $11.1 Million
Q3 2023 Nov 13, 2023	BUY	$20.13 - $27.29 $805,361 - $1.09 Million	40,008 Added 9.66%	454,331 $10.7 Million
Q2 2023 Aug 11, 2023	SELL	$18.33 - $27.18 $1.11 Million - $1.64 Million	-60,329 Reduced 12.71%	414,323 $10.9 Million
Q1 2023 May 12, 2023	BUY	$14.25 - $20.5 $356,250 - $512,500	25,000 Added 5.56%	474,652 $8.73 Million
Q4 2022 Feb 13, 2023	BUY	$12.8 - $23.66 $5.76 Million - $10.6 Million	449,652 New	449,652 $6.96 Million

202

62.2M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.89B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

Stay updated on Carmignac Gestion with notifications on news.